Veracyte, Inc. (VCYT)

NGM – Real Time Price. Currency in USD

46.01

-0.40 (-0.86%)

Market open: Aug 12, 2026, 11:36 AM EDT

46.50

+0.09 (0.19%)

Previous after-hours: Aug 11, 2026, 7:45 PM EDT

10.08.2026

Veracyte: Diagnostics With Favorable Economics

Veracyte's core tests are Decipher and Afirma. Both of these tests are producing double-digit growth with improving margins. I think that bodes well for VCYT's potential as a long-term cash flow machine. Moreover, VCYT's Prosigna and TrueMRD add more long-term upside, which management hasn't yet included in its recent 2026 testing-revenue guidance.

10.08.2026

Veracyte: Core Growth Funds Prosigna And TrueMRD

Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence, specialist relationships, and reimbursement infrastructure. Q2 2026 results showed 15% revenue growth, 23% adjusted EBITDA growth, and 29.2% EBITDA margin, with robust cash generation and no funded debt. Prosigna and TrueMRD launches offer significant upside, as 2026 guidance excludes their contributions, while Decipher and Afirma drive core growth and margin expansion.

Videos

No Data

There is no data to display

Veracyte, Inc. (VCYT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Veracyte, Inc. (VCYT)

Veracyte: Diagnostics With Favorable Economics

Veracyte: Core Growth Funds Prosigna And TrueMRD

Videos

No Data

Veracyte: Diagnostics With Favorable Economics

Veracyte: Core Growth Funds Prosigna And TrueMRD

Videos

No Data

Search stocks

Veracyte, Inc. (VCYT)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Veracyte, Inc. (VCYT)

Veracyte: Diagnostics With Favorable Economics

Veracyte: Core Growth Funds Prosigna And TrueMRD

Videos

No Data

Veracyte: Diagnostics With Favorable Economics

Veracyte: Core Growth Funds Prosigna And TrueMRD

Videos

No Data